{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:alpha-adrenergic-blockers-and-central-alpha-2-agonists",
  "owner": "cardio",
  "kind": "drug",
  "slug": "alpha-adrenergic-blockers-and-central-alpha-2-agonists",
  "name": "Alpha-adrenergic blockers and central alpha-2 agonists",
  "aliases": [
    "Alpha blockers",
    "Adrenergic alpha-antagonists",
    "Central alpha-2 agonists"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Two groups of medicines that lower blood pressure through the alpha-adrenergic system. The alpha blockers block alpha-adrenergic receptors; MeSH says they are used in high blood pressure, vasospasm, peripheral vascular disease, shock and pheochromocytoma. The central alpha-2 agonists act through the central nervous system. The US labels read for one of each list high blood pressure, and the alpha blocker label lists prostate enlargement as well.",
  "summary_technical": "Class page for two related groups, written as one because the plan combined them. MeSH descriptors D000317 (Adrenergic alpha-Antagonists, last updated 2018-06-14) and D058647 (Adrenergic alpha-2 Receptor Agonists, last updated 2011-01-01) are both broad matches, because neither alone is the whole page. Two US labels were read. CARDURA (doxazosin tablets, application NDA019668, effective 2023-10-15 in openFDA) calls the medicine an alpha 1 adrenergic antagonist and lists benign prostatic hyperplasia and hypertension. Catapres-TTS (clonidine transdermal system, application NDA018891, effective 2026-01-06 in openFDA) is indicated for hypertension, describes clonidine as a centrally acting agent, and the openFDA record gives the established pharmacologic class Central alpha-2 Adrenergic Agonist. The second MeSH scope note is only one sentence. This page gives no dose, no trial result and no guideline statement; no warning in either label was recorded. Medicines of the groups that have their own pages are filed under it.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-09",
  "last_evidence_check": "2026-11-09",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "mesh",
      "value": "D000317",
      "normalized_value": "D000317",
      "match": "broad",
      "version": "MeSH linked-data descriptor record fetched on 2026-11-09, lastUpdated 2018-06-14; the record states no yearly MeSH release",
      "label": "Adrenergic alpha-Antagonists",
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D058647",
      "normalized_value": "D058647",
      "match": "broad",
      "version": "MeSH linked-data descriptor record fetched on 2026-11-09, lastUpdated 2011-01-01; the record states no yearly MeSH release",
      "label": "Adrenergic alpha-2 Receptor Agonists",
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels"
      ],
      "condition-area": [
        "hypertension"
      ]
    }
  },
  "payload": {
    "level": "class",
    "mechanism": "MeSH says alpha-antagonists bind to alpha-adrenergic receptors without activating them, and so block the actions of adrenergic agonists. A US label says clonidine reduces sympathetic outflow from the central nervous system."
  },
  "content_digest": "9909b795268356a22ed4e507ad06a749666b660a7d7468dc8f55787bb8affa9a",
  "review": {
    "content_digest": "9909b795268356a22ed4e507ad06a749666b660a7d7468dc8f55787bb8affa9a",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-alpha-labels-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:alpha-adrenergic-blockers-and-central-alpha-2-agonists",
      "category": "descriptive",
      "statement": "Two US labels were read. The label of CARDURA (doxazosin tablets, Viatris Specialty LLC, application NDA019668; the version dated 2023-10-15 in openFDA) calls the medicine an alpha 1 adrenergic antagonist and lists the signs and symptoms of benign prostatic hyperplasia and the treatment of hypertension. The label of Catapres-TTS (clonidine transdermal system, Technomed Inc., application NDA018891; the version dated 2026-01-06 in openFDA) says it is indicated in the treatment of hypertension and describes clonidine as a centrally acting agent; openFDA's record gives the established pharmacologic class Central alpha-2 Adrenergic Agonist. MeSH says alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock and pheochromocytoma.",
      "context": {
        "id": "cardio:ctx-fda-alpha-labels-us",
        "label": "People with hypertension, and men with benign prostatic hyperplasia for the alpha blocker, as described in two US labels",
        "recipient": "unknown",
        "population": "Patients described in the indications sections of the two labels: patients with hypertension, and for the alpha blocker label also patients with the signs and symptoms of benign prostatic hyperplasia.",
        "care_setting": "Prescription medicine, as described in the US labels",
        "geography": "United States (US drug labels)",
        "life_stage_note": "Not stated in the passages read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Hypertension",
            "Signs and symptoms of benign prostatic hyperplasia (alpha blocker label only)"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what two US labels say. It is not a finding about how well either medicine works, and no trial result is recorded for it in this atlas. The prostate indication belongs to the alpha blocker label only. The pharmacologic class name for the second medicine comes from openFDA's record of its label. The second label is for a skin patch; an oral form of the same medicine was not read. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-09",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Alpha 1 adrenergic antagonist; BPH and hypertension.",
          "snapshot": {
            "id": "cardio:openfda-label-cardura-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:42Z",
            "content_hash": "2493e9d5346ff8f7d721f288aecee512a7d67a1a821ff0bc5d51ecc0e171f615",
            "source_effective_date": "2023-10-15",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-cardura",
            "source_type": "regulator",
            "title": "openFDA drug label record for CARDURA (doxazosin tablets), Viatris Specialty LLC label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%225e1f5e49-2da1-43ab-9795-228a8bcc5a82%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 5e1f5e49-2da1-43ab-9795-228a8bcc5a82 (manufacturer Viatris Specialty LLC, application NDA019668), returned on 2026-11-09. The label text is dated 2023-10-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-cardura.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20231015.",
          "snapshot": {
            "id": "cardio:openfda-label-cardura-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:42Z",
            "content_hash": "2493e9d5346ff8f7d721f288aecee512a7d67a1a821ff0bc5d51ecc0e171f615",
            "source_effective_date": "2023-10-15",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-cardura",
            "source_type": "regulator",
            "title": "openFDA drug label record for CARDURA (doxazosin tablets), Viatris Specialty LLC label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%225e1f5e49-2da1-43ab-9795-228a8bcc5a82%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 5e1f5e49-2da1-43ab-9795-228a8bcc5a82 (manufacturer Viatris Specialty LLC, application NDA019668), returned on 2026-11-09. The label text is dated 2023-10-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-cardura.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], INDICATIONS AND USAGE",
          "applicability_note": "Hypertension use of the clonidine patch.",
          "snapshot": {
            "id": "cardio:openfda-label-catapres-tts-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:44Z",
            "content_hash": "25b034f47f06bcd1ee51201e6a4304164ccc881c2f64f9b3b48af68ba3e7be66",
            "source_effective_date": "2026-01-06",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-catapres-tts",
            "source_type": "regulator",
            "title": "openFDA drug label record for Catapres-TTS (clonidine transdermal system), Technomed Inc. label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2239e1d35e-533c-4647-8649-8168a6e92dfa%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 39e1d35e-533c-4647-8649-8168a6e92dfa (manufacturer Technomed Inc., application NDA018891), returned on 2026-11-09. The label text is dated 2026-01-06 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-catapres-tts.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].openfda.pharm_class_epc[0]",
          "applicability_note": "Established pharmacologic class in openFDA: Central alpha-2 Adrenergic Agonist.",
          "snapshot": {
            "id": "cardio:openfda-label-catapres-tts-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:44Z",
            "content_hash": "25b034f47f06bcd1ee51201e6a4304164ccc881c2f64f9b3b48af68ba3e7be66",
            "source_effective_date": "2026-01-06",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-catapres-tts",
            "source_type": "regulator",
            "title": "openFDA drug label record for Catapres-TTS (clonidine transdermal system), Technomed Inc. label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2239e1d35e-533c-4647-8649-8168a6e92dfa%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 39e1d35e-533c-4647-8649-8168a6e92dfa (manufacturer Technomed Inc., application NDA018891), returned on 2026-11-09. The label text is dated 2026-01-06 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-catapres-tts.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260106.",
          "snapshot": {
            "id": "cardio:openfda-label-catapres-tts-2026-11-09",
            "retrieved_at": "2026-11-09T13:17:44Z",
            "content_hash": "25b034f47f06bcd1ee51201e6a4304164ccc881c2f64f9b3b48af68ba3e7be66",
            "source_effective_date": "2026-01-06",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-catapres-tts",
            "source_type": "regulator",
            "title": "openFDA drug label record for Catapres-TTS (clonidine transdermal system), Technomed Inc. label: indications and class description",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2239e1d35e-533c-4647-8649-8168a6e92dfa%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 39e1d35e-533c-4647-8649-8168a6e92dfa (manufacturer Technomed Inc., application NDA018891), returned on 2026-11-09. The label text is dated 2026-01-06 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k03-openfda-label-catapres-tts.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "scopeNote.@value",
          "applicability_note": "MeSH scope note: uses of alpha-antagonists.",
          "snapshot": {
            "id": "cardio:mesh-scope-d000317-2026-11-09",
            "retrieved_at": "2026-11-09T13:15:47Z",
            "content_hash": "5e459df894b106c7bfd5f9d8996b03f3c29594b42073a810102193c01b8cfc4c",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:mesh-scope-d000317",
            "source_type": "dataset",
            "title": "MeSH scope note for descriptor D000317 (Adrenergic alpha-Antagonists)",
            "canonical_url": "https://id.nlm.nih.gov/mesh/M0000493",
            "identifiers": [
              {
                "scheme": "mesh",
                "value": "M0000493",
                "normalized_value": "M0000493",
                "match": "exact",
                "version": "id.nlm.nih.gov linked data, preferred concept of descriptor D000317, retrieved 2026-11-09",
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": null,
            "publisher": "U.S. National Library of Medicine",
            "edition": "MeSH linked-data record of the preferred concept M0000493 of descriptor D000317, fetched 2026-11-09. The scope note is on this concept record, not on the descriptor record.",
            "reuse_basis": "The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-11-09 and may not reflect the most current data. The raw bytes are committed at research/snapshots/w4k03-meshc-M0000493.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "6ac6fec5ca11aab3b38c31d2d2c12f87c42b5eb5fea8aeac4afa75edb6201c4d",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-alpha-labels-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "evaluated_for",
        "label": "Two US labels list treating high blood pressure as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "core:hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-alpha-labels-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "Blood pressure lowering medicine, the care strategy",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:bp-lowering-medicine",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:clonidine",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-2599-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/alpha-adrenergic-blockers-and-central-alpha-2-agonists/",
  "context_path": "api/v1/context/cardio--alpha-adrenergic-blockers-and-central-alpha-2-agonists.md"
}
